Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

Low Caspofungin Exposure in Patients in Intensive Care Units.

van der Elst KC, Veringa A, Zijlstra JG, Beishuizen A, Klont R, Brummelhuis-Visser P, Uges DR, Touw DJ, Kosterink JG, van der Werf TS, Alffenaar JC.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01582-16. doi: 10.1128/AAC.01582-16. Print 2017 Feb.

2.

4-Aminopyridine as a life-saving treatment in calcium channel antagonist intoxication.

van der Voort PH, Wilffert B, van Roon EN, Uges DR.

Neth J Med. 2016 Jul;74(6):276. No abstract available.

3.

Substance use in individuals with mild to borderline intellectual disability: A comparison between self-report, collateral-report and biomarker analysis.

VanDerNagel JE, Kiewik M, van Dijk M, Didden R, Korzilius HP, van der Palen J, Buitelaar JK, Uges DR, Koster RA, de Jong CA.

Res Dev Disabil. 2017 Apr;63:151-159. doi: 10.1016/j.ridd.2016.04.006. Epub 2016 Apr 25.

PMID:
27133469
4.

Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations.

Encalada Ventura MA, van Wanrooy MJ, Span LF, Rodgers MG, van den Heuvel ER, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2727-31. doi: 10.1128/AAC.02830-15. Print 2016 May.

5.

Voriconazole Therapeutic Drug Monitoring Practices in Intensive Care.

van Wanrooy MJ, Rodgers MG, Span LF, Zijlstra JG, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW.

Ther Drug Monit. 2016 Jun;38(3):313-8. doi: 10.1097/FTD.0000000000000284.

PMID:
26845112
6.

Subtherapeutic Posaconazole Exposure and Treatment Outcome in Patients With Invasive Fungal Disease.

van der Elst KC, Brouwers CH, van den Heuvel ER, van Wanrooy MJ, Uges DR, van der Werf TS, Kosterink JG, Span LF, Alffenaar JW.

Ther Drug Monit. 2015 Dec;37(6):766-71. doi: 10.1097/FTD.0000000000000235.

PMID:
26565789
7.

Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors.

Boer H, Proost JH, Nuver J, Bunskoek S, Gietema JQ, Geubels BM, Altena R, Zwart N, Oosting SF, Vonk JM, Lefrandt JD, Uges DR, Meijer C, de Vries EG, Gietema JA.

Ann Oncol. 2015 Nov;26(11):2305-10. doi: 10.1093/annonc/mdv369. Epub 2015 Sep 7.

8.

The relation of the number of hydrogen-bond acceptors with recoveries of immunosuppressants in DBS analysis.

Koster RA, Alffenaar JW, Botma R, Greijdanus B, Uges DR, Kosterink JG, Touw DJ.

Bioanalysis. 2015;7(14):1717-22. doi: 10.4155/bio.15.94.

PMID:
26270779
9.

The performance of five different dried blood spot cards for the analysis of six immunosuppressants.

Koster RA, Botma R, Greijdanus B, Uges DR, Kosterink JG, Touw DJ, Alffenaar JW.

Bioanalysis. 2015;7(10):1225-35. doi: 10.4155/bio.15.63.

PMID:
26045003
10.

An interlaboratory quality control programme for the measurement of tuberculosis drugs.

Aarnoutse RE, Sturkenboom MG, Robijns K, Harteveld AR, Greijdanus B, Uges DR, Touw DJ, Alffenaar JW.

Eur Respir J. 2015 Jul;46(1):268-71. doi: 10.1183/09031936.00177014. Epub 2015 Apr 16. No abstract available.

11.

What is the right blood hematocrit preparation procedure for standards and quality control samples for dried blood spot analysis?

Koster RA, Alffenaar JW, Botma R, Greijdanus B, Touw DJ, Uges DR, Kosterink JG.

Bioanalysis. 2015;7(3):345-51. doi: 10.4155/bio.14.298.

PMID:
25697192
12.

Limited-sampling strategies for anidulafungin in critically ill patients.

van Wanrooy MJ, Proost JH, Rodgers MG, Zijlstra JG, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2015 Feb;59(2):1177-81. doi: 10.1128/AAC.03375-14. Epub 2014 Dec 8.

13.

Inflammation is associated with voriconazole trough concentrations.

van Wanrooy MJ, Span LF, Rodgers MG, van den Heuvel ER, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2014 Dec;58(12):7098-101. doi: 10.1128/AAC.03820-14. Epub 2014 Sep 15.

14.

Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations.

Lempers VJ, Alffenaar JW, Touw DJ, Burger DM, Uges DR, Aarnoutse RE, Brüggemann RJ.

J Antimicrob Chemother. 2014 Nov;69(11):2988-94. doi: 10.1093/jac/dku242. Epub 2014 Jul 7.

PMID:
25006236
15.

Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS.

Vu DH, Koster RA, Bolhuis MS, Greijdanus B, Altena RV, Nguyen DH, Brouwers JR, Uges DR, Alffenaar JW.

Talanta. 2014 Apr;121:9-17. doi: 10.1016/j.talanta.2013.12.043. Epub 2013 Dec 27.

PMID:
24607103
16.

Assessing the availability of the teratogenic drug isotretinoin outside the pregnancy prevention programme: a survey of e-pharmacies.

Lagan BM, Dolk H, White B, Uges DR, Sinclair M.

Pharmacoepidemiol Drug Saf. 2014 Apr;23(4):411-8. doi: 10.1002/pds.3565. Epub 2014 Feb 3.

17.

Low but sufficient anidulafungin exposure in critically ill patients.

van Wanrooy MJ, Rodgers MG, Uges DR, Arends JP, Zijlstra JG, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2014;58(1):304-8. doi: 10.1128/AAC.01607-13. Epub 2013 Oct 28.

18.

Simultaneous quantification of anidulafungin and caspofungin in plasma by an accurate and simple liquid chromatography tandem mass-spectrometric method.

van Wanrooy MJ, Santoe RN, van der Elst KC, Wilmer CM, van Hateren K, Wessels AM, Greijdanus B, Alffenaar JW, Uges DR.

Ther Drug Monit. 2013 Dec;35(6):778-84. doi: 10.1097/FTD.0b013e31829591a7.

PMID:
24081203
19.

Fast and highly selective LC-MS/MS screening for THC and 16 other abused drugs and metabolites in human hair to monitor patients for drug abuse.

Koster RA, Alffenaar JW, Greijdanus B, VanDernagel JE, Uges DR.

Ther Drug Monit. 2014 Apr;36(2):234-43. doi: 10.1097/FTD.0b013e3182a377e8.

PMID:
24071815
20.

Application of sweat patch screening for 16 drugs and metabolites using a fast and highly selective LC-MS/MS method.

Koster RA, Alffenaar JW, Greijdanus B, VanDerNagel JE, Uges DR.

Ther Drug Monit. 2014 Feb;36(1):35-45. doi: 10.1097/FTD.0b013e3182a04feb.

PMID:
24071814
21.

Fast LC-MS/MS analysis of tacrolimus, sirolimus, everolimus and cyclosporin A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery.

Koster RA, Alffenaar JW, Greijdanus B, Uges DR.

Talanta. 2013 Oct 15;115:47-54. doi: 10.1016/j.talanta.2013.04.027. Epub 2013 Apr 19.

PMID:
24054560
22.

Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis.

Dalbøge CS, Nielsen XC, Dalhoff K, Alffenaar JW, Duno M, Buchard A, Uges DR, Jensen AG, Jürgens G, Pressler T, Johansen HK, Høiby N.

J Cyst Fibros. 2014 Mar;13(2):179-85. doi: 10.1016/j.jcf.2013.08.008. Epub 2013 Sep 10.

23.

Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole.

van der Elst KC, Span LF, van Hateren K, Vermeulen KM, van der Werf TS, Greijdanus B, Kosterink JG, Uges DR, Alffenaar JW.

Antimicrob Agents Chemother. 2013 Oct;57(10):4999-5004. doi: 10.1128/AAC.00707-13. Epub 2013 Jul 29.

24.

Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis.

Bolhuis MS, van Altena R, van Hateren K, de Lange WC, Greijdanus B, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2013 Aug;57(8):3676-80. doi: 10.1128/AAC.00558-13. Epub 2013 May 20.

25.

Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients.

Bolhuis MS, van Altena R, van Soolingen D, de Lange WC, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW.

Eur Respir J. 2013 Dec;42(6):1614-21. doi: 10.1183/09031936.00001913. Epub 2013 Mar 21.

26.

Troubleshooting carry-over of LC-MS/MS method for rifampicin, clarithromycin and metabolites in human plasma.

Vu DH, Koster RA, Wessels AM, Greijdanus B, Alffenaar JW, Uges DR.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Feb 15;917-918:1-4. doi: 10.1016/j.jchromb.2012.12.023. Epub 2013 Jan 10.

PMID:
23353809
27.

Intratumoral administration of holmium-166 acetylacetonate microspheres: antitumor efficacy and feasibility of multimodality imaging in renal cancer.

Bult W, Kroeze SG, Elschot M, Seevinck PR, Beekman FJ, de Jong HW, Uges DR, Kosterink JG, Luijten PR, Hennink WE, van het Schip AD, Bosch JL, Nijsen JF, Jans JJ.

PLoS One. 2013;8(1):e52178. doi: 10.1371/journal.pone.0052178. Epub 2013 Jan 8.

28.

Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.

Vu DH, Bolhuis MS, Koster RA, Greijdanus B, de Lange WC, van Altena R, Brouwers JR, Uges DR, Alffenaar JW.

Antimicrob Agents Chemother. 2012 Nov;56(11):5758-63. doi: 10.1128/AAC.01054-12. Epub 2012 Aug 27.

29.

Effect of preventive supplementation with zinc and other micronutrients on non-malarial morbidity in Tanzanian pre-school children: a randomized trial.

Veenemans J, Schouten LR, Ottenhof MJ, Mank TG, Uges DR, Mbugi EV, Demir AY, Kraaijenhagen RJ, Savelkoul HF, Verhoef H.

PLoS One. 2012;7(8):e41630. doi: 10.1371/journal.pone.0041630. Epub 2012 Aug 3.

30.

Determination of ribavirin in human serum using liquid chromatography tandem mass spectrometry.

van der Lijke H, Alffenaar JW, Kok WT, Greijdanus B, Uges DR.

Talanta. 2012 Jan 15;88:385-90. doi: 10.1016/j.talanta.2011.11.004. Epub 2011 Nov 6.

PMID:
22265514
31.

Effect of supplementation with zinc and other micronutrients on malaria in Tanzanian children: a randomised trial.

Veenemans J, Milligan P, Prentice AM, Schouten LR, Inja N, van der Heijden AC, de Boer LC, Jansen EJ, Koopmans AE, Enthoven WT, Kraaijenhagen RJ, Demir AY, Uges DR, Mbugi EV, Savelkoul HF, Verhoef H.

PLoS Med. 2011 Nov;8(11):e1001125. doi: 10.1371/journal.pmed.1001125. Epub 2011 Nov 22.

32.

Dried blood spots: a new tool for tuberculosis treatment optimization.

Vu DH, Alffenaar JW, Edelbroek PM, Brouwers JR, Uges DR.

Curr Pharm Des. 2011;17(27):2931-9. Review.

PMID:
21834763
33.

Validation parameters cannot be obtained without using pure substance.

van der Elst KC, Uges DR, Alffenaar JW.

J Pharm Biomed Anal. 2011 Sep 10;56(2):462-3; author reply 462-3. doi: 10.1016/j.jpba.2011.04.021. Epub 2011 Apr 28. No abstract available.

PMID:
21632195
34.

Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis.

Pranger AD, Kosterink JG, van Altena R, Aarnoutse RE, van der Werf TS, Uges DR, Alffenaar JW.

Ther Drug Monit. 2011 Jun;33(3):350-4. doi: 10.1097/FTD.0b013e31821b793c.

PMID:
21544017
35.

Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume.

Vu DH, Koster RA, Alffenaar JW, Brouwers JR, Uges DR.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 May 1;879(15-16):1063-70. doi: 10.1016/j.jchromb.2011.03.017. Epub 2011 Mar 16.

PMID:
21459055
36.

Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience.

Pranger AD, van Altena R, Aarnoutse RE, van Soolingen D, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW.

Eur Respir J. 2011 Oct;38(4):888-94. doi: 10.1183/09031936.00176610. Epub 2011 Feb 10.

37.

Clarithromycin significantly increases linezolid serum concentrations.

Bolhuis MS, van Altena R, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2010 Dec;54(12):5418-9. doi: 10.1128/AAC.00757-10. Epub 2010 Sep 13. No abstract available.

38.

The relationship between benzodiazepine use and traffic accidents: A systematic literature review.

Smink BE, Egberts AC, Lusthof KJ, Uges DR, de Gier JJ.

CNS Drugs. 2010 Aug;24(8):639-53. doi: 10.2165/11533170-000000000-00000. Review.

PMID:
20658797
39.

Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.

Alffenaar JW, van Altena R, Harmelink IM, Filguera P, Molenaar E, Wessels AM, van Soolingen D, Kosterink JG, Uges DR, van der Werf TS.

Clin Pharmacokinet. 2010 Aug;49(8):559-65. doi: 10.2165/11532080-000000000-00000.

PMID:
20608757
40.

Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection.

Alffenaar JW, Nienhuis WA, de Velde F, Zuur AT, Wessels AM, Almeida D, Grosset J, Adjei O, Uges DR, van der Werf TS.

Antimicrob Agents Chemother. 2010 Sep;54(9):3878-83. doi: 10.1128/AAC.00099-10. Epub 2010 Jun 28.

41.
42.

Intravenous voriconazole after toxic oral administration.

Alffenaar JW, van Assen S, de Monchy JG, Uges DR, Kosterink JG, van der Werf TS.

Antimicrob Agents Chemother. 2010 Jun;54(6):2741-2. doi: 10.1128/AAC.01193-09. Epub 2010 Apr 12.

43.

Gemcitabine and epirubicin plasma concentration-related excretion in saliva in patients with non-small cell lung cancer.

Maring JG, Wachters FM, Maurer M, Uges DR, de Vries EG, Groen HJ.

Ther Drug Monit. 2010 Jun;32(3):364-8. doi: 10.1097/FTD.0b013e3181d631a6.

PMID:
20335827
44.

Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.

Maring JG, Wachters FM, Slijfer M, Maurer JM, Boezen HM, Uges DR, de Vries EG, Groen HJ.

Eur J Clin Pharmacol. 2010 Jun;66(6):611-7. doi: 10.1007/s00228-010-0799-0. Epub 2010 Mar 6.

45.

Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.

Alffenaar JW, Kosterink JG, van Altena R, van der Werf TS, Uges DR, Proost JH.

Ther Drug Monit. 2010 Feb;32(1):97-101. doi: 10.1097/FTD.0b013e3181cc6d6f.

PMID:
20042919
46.

Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS.

Alffenaar JW, Wessels AM, van Hateren K, Greijdanus B, Kosterink JG, Uges DR.

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jan 1;878(1):39-44. doi: 10.1016/j.jchromb.2009.11.017.

PMID:
19945360
47.

Neurophysiological evaluation in children with Friedreich's ataxia.

Sival DA, du Marchie Sarvaas GJ, Brouwer OF, Uges DR, Verschuuren-Bemelmans CC, Maurits NM, Brunt ER, van der Hoeven JH.

Early Hum Dev. 2009 Oct;85(10):647-51. doi: 10.1016/j.earlhumdev.2009.09.002. Epub 2009 Sep 22.

PMID:
19775837
48.

Phenytoin-induced reduction of voriconazole serum concentration is not compensated by doubling the dosage.

Alffenaar JW, van der Elst KC, Uges DR, Kosterink JG, Daenen SM.

Br J Clin Pharmacol. 2009 Sep;68(3):462-3. doi: 10.1111/j.1365-2125.2009.03464.x. No abstract available.

49.

Increased intestinal permeability in deceased brain dead rats.

Koudstaal LG, Ottens PJ, Uges DR, Ploeg RJ, van Goor H, Leuvenink HG.

Transplantation. 2009 Aug 15;88(3):444-6. doi: 10.1097/TP.0b013e3181af39bd. No abstract available.

PMID:
19667953
50.

Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography-tandem mass spectrometry.

de Velde F, Alffenaar JW, Wessels AM, Greijdanus B, Uges DR.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jun 15;877(18-19):1771-7. doi: 10.1016/j.jchromb.2009.04.038. Epub 2009 May 3.

PMID:
19457725

Supplemental Content

Support Center